Volume : IX, Issue : X, October - 2019

Risk for Febrile Neutropenia among Patients Undergoing Chemotherapy

Dr. Thenmozhi. P, Nishanthi. D

Abstract :

Introduction: Feile Neutropenia is a rapid decline in absolute neutrophil count is developed in response to the effects of chemotherapy in seven to fourteen days after treatment which increase the morbidity and mortality of patients receiving chemotherapy. Hence the study was conducted with aimed to assess the level of risk for feile neutropenia among patients undergoing chemotherapy. Materials and Methods: Descriptive study design was employed with 100 samples who matched the inclusion criteria were selected by convenience sampling technique. Demographic variables were collected by using multiple choice questionnaires followed by MASCC (Multinational Association for Supportive Care in Cancer) FN risk index score scale were used to collect data to assess the level of risk for feile neutropenia. The data were tabulated and analyzed by descriptive and inferential statistics. Results: The finding of the study reveals that 58% were on high risk for feile neutropenia and 42% were on low risk for feile neutropenia. Conclusion: special precautions to be followed prevent the infection along with administration of biological therapies to boost the immune system. Educate the health care personnel regarding feile neutropenia risk assessment and its management.

Keywords :

Article: Download PDF    DOI : 10.36106/ijar  

Cite This Article:

RISK FOR FEBRILE NEUTROPENIA AMONG PATIENTS UNDERGOING CHEMOTHERAPY, Dr.Thenmozhi.P, Nishanthi.D INDIAN JOURNAL OF APPLIED RESEARCH : Volume-9 | Issue-10 | October-2019

Number of Downloads : 139

References :